AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Does inhibiting TMEM16F actually reduce the symptoms of Parkinson's disease? Does the lipid composition of cell membranes ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Does inhibiting TMEM16F actually reduce the symptoms of Parkinson's disease? Does the lipid composition of cell membranes ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

In addition, they often have milder symptoms, especially in the early stages ... could be a promising candidate diagnostic ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...